Body Contouring Surgery After GLP-1 Weight Loss Has Similar Complication Rates to Other Methods | Research

The takeaway

Patients who lost weight with GLP-1 medications had similar body contouring surgery complication rates as those who lost weight through bariatric surgery, lifestyle changes, or combination therapy.

No difference in complication rates by weight loss method
Among 1,002 body contouring patients, GLP-1 users had similar surgical outcomes to those who lost weight through bariatric surgery or lifestyle changes

What the researchers found

Among 1,002 post-weight loss body contouring patients, complication rates did not differ significantly by weight loss method across all procedure types (panniculectomy, brachioplasty, thighplasty, breast surgery). Weight loss methods included bariatric surgery (67.9%), lifestyle modification (14.3%), combination therapy (10.1%), and GLP-1 pharmacotherapy alone (7.8%).

BMI at the time of surgery and diabetes were identified as independent predictors of increased postoperative complications, regardless of how the weight was lost. Each procedure type showed its own expected complication patterns, but the method of weight loss was not a factor.

Why it matters

The explosion in GLP-1 medication use has driven a parallel surge in demand for body contouring surgery. Surgeons and patients have had little data on whether GLP-1-mediated weight loss carries different surgical risks compared to traditional methods. This study provides the first substantial evidence that the weight loss method doesn't matter — only the patient's condition at the time of surgery does.

How the study worked

This was a single-center, retrospective cohort study of patients who underwent post-weight loss body contouring surgery between January 2019 and December 2024. Eligible patients were adults who achieved weight loss and then had panniculectomy, brachioplasty, thighplasty, or breast surgery. Patients were classified into four groups by weight loss method. The primary outcome was the incidence of postoperative complications within 90 days for each procedure.

What this study cannot tell us

Single-center retrospective study, which limits generalizability. Baseline characteristics differed significantly across weight loss groups, which may confound comparisons despite statistical adjustments. The GLP-1-only group was relatively small (7.8% of 1,002 = ~78 patients), limiting statistical power to detect differences. The study period (2019-2024) captures early GLP-1 adoption, and patients on newer high-dose regimens may differ. Complications were tracked for only 90 days, missing potential longer-term issues.

How to read the evidence

This is a retrospective cohort study from a single center with a good sample size (1,002 patients). While retrospective studies are lower quality than randomized trials, this design is appropriate for the research question. The relatively small GLP-1 subgroup is a limitation.

When this study was published

Published in 2026 with data through December 2024, this is an extremely current study addressing a rapidly evolving clinical question driven by the GLP-1 medication boom.

The bigger picture

Body contouring after GLP-1-induced weight loss is one of the fastest-growing areas of plastic surgery. This study addresses a critical safety question that has been debated among surgeons: whether the rapid, pharmacologically-driven weight loss from GLP-1 drugs somehow changes body composition or tissue quality in ways that affect surgical outcomes. The answer appears to be no, which should help standardize patient selection criteria.

Questions still open

Do patients who lose weight on GLP-1 drugs have different skin elasticity or tissue quality that affects long-term cosmetic outcomes even if complication rates are similar?
Should GLP-1 medications be continued, paused, or stopped around the time of body contouring surgery?
Will complication rates change as GLP-1 users who achieve greater weight loss (with newer higher doses) seek body contouring?

Common questions

Is it safe to get body contouring surgery after losing weight on Ozempic or Wegovy?

This study of over 1,000 patients suggests yes — complication rates for body contouring surgery were similar regardless of whether patients lost weight through GLP-1 medications, bariatric surgery, or lifestyle changes. The most important factors for surgical safety were your BMI at the time of surgery and whether you have diabetes, not how you lost the weight.

Should I stop my GLP-1 medication before body contouring surgery?

This study did not specifically address medication timing around surgery. GLP-1 medications can slow stomach emptying, which some anesthesiologists have flagged as a concern for aspiration risk during surgery. Discuss with your surgeon and anesthesiologist about whether and when to pause your medication before the procedure.

Read the original research

Post-weight Loss Body Contouring Surgery: Complication Rates Following Bariatric Surgery, Injectable GLP-1 Pharmacotherapy, Combination Therapy, and Lifestyle Modification.

Aesthetic surgery journal

View on PubMed ↗Publisher’s paper ↗

Citation

Abbott, Erin N; Giannas, Emmanuel; Dorjsuren, Nomongo; King, Daniella; Li, Ruoying; Christopher, Adrienne; Gergoudis, Franklin; Gabriel, Allen; Perdikis, Galen; Assi, Patrick. (2026). Post-weight Loss Body Contouring Surgery: Complication Rates Following Bariatric Surgery, Injectable GLP-1 Pharmacotherapy, Combination Therapy, and Lifestyle Modification.. Aesthetic surgery journal. https://doi.org/10.1093/asj/sjag049